Internal Medicine Alert
RSSArticles
-
Long-Term Air Pollution Exposure Could Raise Risk for Depression, Anxiety
Two research groups reported on breathing dirty air and how that affects mental health.
-
A Patient with Pneumonia
The ECG in the figure was obtained from an elderly man who was admitted to the hospital with pneumonia. This ECG was obtained after his admission when he began to complain of chest pain. There are two important findings on this patient’s ECG. Can you identify them?
-
Lecanemab-irmb Injection (Leqembi)
Lecanemab can be prescribed to treat Alzheimer's disease. Initiate this treatment in patients with mild cognitive impairment or mild dementia stage of disease, with confirmation of amyloid beta pathology.
-
Vaccination Against Mpox: Does It Work? Is It Safe?
Vaccination, either subcutaneously or intradermally, with the non-replicating Jynneos monkeypox vaccine is safe and effective.
-
Resistance of SARS-CoV-2 Variants to Monoclonal Antibodies
Prevalent SARS-CoV-2 variants are persistently resistant to therapeutic and prophylactic monoclonal antibodies but remain susceptible to nirmatrelvir/ritonavir, remdesivir, and molnupiravir.
-
Chlorthalidone vs. Hydrochlorothiazide: Which Is Superior for Treating Hypertension?
Randomly switching half of patients with hypertension on hydrochlorothiazide to chlorthalidone did not produce any difference in major cardiovascular outcomes.
-
For Older Americans, More Steps Lead to Better Cardiovascular Health
In a meta-analysis, researchers found walking 6,000 to 9,000 steps daily lowered the risk of cardiovascular disease by 40% to 50% vs. walking 2,000 steps daily.
-
Tocilizumab Injection (Actemra)
The FDA has approved tocilizumab injection to treat COVID-19 among hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen.
-
Current and Future Options for Male Contraception
The following is a summary of the existing male contraceptive options and an overview of future ones.
-
New Therapy for Resistant Hypertension
Aprocitentan demonstrated efficacy for additional therapy beyond standard multidrug treatment in resistant hypertension.